Every 424B that SOPHiA GENETICS SA (SOPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SOPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOPH filings page.
SOPHiA GENETICS is offering 10,526,000 ordinary shares at a public offering price of $4.75 per share, with an underwriters’ option to purchase up to an additional 1,578,900 ordinary shares for 30 days after this prospectus supplement. The offering is expected to raise gross proceeds of approximately $49,998,500 before underwriting discounts and commissions.
Net proceeds to the company are shown as approximately $46,998,590 (before expenses) and estimated net proceeds are approximately $45.9 million. Shares outstanding used for dilution calculations are listed as 71,790,366 ordinary shares as of March 31, 2026. The ordinary shares trade on Nasdaq under the symbol SOPH.
SOPHiA GENETICS is offering ordinary shares pursuant to a preliminary prospectus supplement dated June 16, 2026. The supplement states the company has granted the underwriters a 30-day option to purchase additional ordinary shares at the public offering price less underwriting discounts and commissions. The company notes 71,790,366 ordinary shares outstanding as of March 31, 2026 and discloses a last reported Nasdaq sale price of $5.01 per share on June 15, 2026. The prospectus supplement describes intended uses of net proceeds for working capital and general corporate purposes, including research and development, sales and marketing, collaborations, regulatory clearances and possible in-licensing or acquisitions; it warns of dilution, lock-up agreements and the potential for future sales to affect the market price.
SOPHiA GENETICS files a resale prospectus to register 75,000 ordinary shares issuable upon exercise of a warrant previously issued to Perceptive Credit Holdings IV, LP. The Second Amendment warrant carries an exercise price of $5.1829 per share and is exercisable for cash until 5:00 p.m. Eastern on January 23, 2036.
The company will not receive proceeds from secondary sales by the selling shareholder; however, if the Second Amendment warrants are exercised in full the company could receive up to $388,717.50, which it says would be used for working capital and general corporate purposes. Shares outstanding were 89,321,220 ordinary shares as of December 31, 2025.